statement. Thanks income Brad. with Starting
a in X.X% For third our $XX generated increase year-over-year revenue top XX.X% to of total XXXX. a QX the increase line, million we compared quarter, and
in As a our this revenue late made third and strategic impacted we have in large growth Absent been decision XX.X%. contract terminate this in year-end the our we our would call, discussed XXXX, quarter. payer growth conference to XXXX a termination,
a For gross XX.X% million, period. over profit increase our quarter, year prior the $XX was the third
gross Our On net XX%. a was the GAAP loss was our million for quarter. $X margin basis,
For the quarter, negative million. our $X.X adjusted EBITDA was
in as our costs Our can XX-Q. well define calculation on as adjusted we EBITDA costs. provider acquisition adjusted EBITDA includes start-up Further found how be details
and quarter-end, equivalent we in million, was cash to moving At million cash sheet. and balance $XX balance Now $XX investments. had our
for our this months. capital expect the and support to sufficient We to XX growth next operations be enhance
Now to guidance. turning
We are range acquisitions. to primarily closing to full million, in a due to our $XXX lowering million $XXX of guidance year of delay top line
Our growth guidance XX% XXXX represents to updated over XX% revenue.
our continued $XX near-term to negative EBITDA profit million. are business margin million Therefore, to lower a million guidance our throughout these supporting lag to $XX we guidance the gross our Despite of our invest $XX in of original seen lowering in have have growth we to $XX due coming profit gross the than gross we negative million our range long-term headwinds, improve is while guidance range revenue. in to to adjusted and Additionally, year, trajectory.
new reminder, XXXX, services. in regarding a January reimbursement policy Medi-Cal implemented of a As pharmacy
be chemotherapy reimbursed was part drugs intended Medi-Cal change to some Medi-Cal guidance benefit. policy though Medi-Cal the to prescription administered be benefits to California to outpatient transition Department administer early pharmacy billed necessary year nevertheless, all available in the of as issued drugs Although, Services through physician of way at claims not payable has our the of the these a Managed the The are Care benefit. under offices began continue Healthcare Medi-Cal clarifying in
in minimal IV dispensed reimbursement. dispensary, insurance, of oncolytics and XXXX otherwise of we impact patients first a some being Medi-Cal currently to this $X respect we the are the covered oral not what million historically drug into XXXX, Medi-Cal our to under fill. our During generated. have of are scripts to which Rx translate to we in certain reduction able three saw chemotherapy quarters now would We we in estimate revenue to have With compared
going actively pharmacy. a or launching opportunities to to the forward, assess continue impact including our acquiring business on We mitigate
available. we in SG&A, our with update spend on are We to will far With information so you once track is XXXX. respect more
We costs We new particular to in to Brad to supporting sites over to turn public adjusted we those now make costs company will are back corporate P&L some EBITDA, investments nor for continue to to targeted new related we and adding growth providers. it infrastructure I summary trajectory. cost are our reemphasize that want back not any or adding start-up in back related remarks.